Conjugated Linoleic Acid Supplementation for Prader-Willi Syndrome
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Prader-Willi Syndrome (PWS) and associated hypogonadism lack effective treatment options, with current therapies failing to adequately address developmental delays, muscle weakness, obesity, and related symptoms.
Innovation Solution
Administration of conjugated linoleic acid (CLA) or its formulations, including dietary supplements, to subjects with Snord116 deficiency or Nhlh2-related hypogonadism, at effective doses of 1,000 mg to 5,000 mg per day or 3-10 g/kg body weight per day, to improve body weight, fat mass, testicular morphology, and modulate gut microbiome and gene expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapies are used for PWS, then treatment coverage is limited, but patient symptoms (obesity, muscle weakness, developmental delays) remain unaddressed
Solution Approach 1:
The patent introduces a novel therapeutic parameter - conjugated linoleic acid (CLA) supplementation at specific dosages (1,000-5,000 mg/day or 3-10 g/kg body weight/day) - to treat PWS symptoms. This chemical parameter change addresses multiple unmet needs simultaneously: reducing obesity through fat mass reduction, improving muscle weakness through lean body mass increase, and potentially addressing developmental delays through metabolic modulation.
2Reliability
If CLA supplementation is administered at high doses (3-10 g/kg body weight per day), then therapeutic effects are enhanced, but dosage complexity increases
Solution Approach 1:
The patent establishes specific dosage parameters (1,000-5,000 mg/day or 3-10 g/kg body weight/day) that optimize therapeutic effects while providing clear guidance for clinical implementation. These parameter specifications transform a potentially complex supplementation strategy into a standardized treatment protocol.
3Quantity of substance
If CLA treatment is used to decrease body weight and fat mass, then obesity symptoms improve, but lean body mass must be preserved
Solution Approach 1:
The patent utilizes CLA's unique metabolic parameter effects to selectively reduce fat mass while preserving or increasing lean body mass. This differential parameter change - reducing adipose tissue while maintaining muscle mass - addresses the dual challenge of obesity treatment and muscle weakness improvement in PWS patients.
Data Source
AI summary
Described in certain example embodiments herein are methods of and compositions for treating a Snordl l6 deficiency disease or symptom thereof with conjugated linoleic acid (CLA) or a formulation thereof. In some embodiments, the Snordl l6 deficiency disease is Prader-Willi Syndrome. Described in certain example embodiments herein are methods of and compositions for treating Nhlh2 associated hypogonadism with CLA or a formulation thereof.